Ibere Pharmaceuticals
IBER
IBER was delisted on the 1st of March, 2023.
48 hedge funds and large institutions have $120M invested in Ibere Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 2 reducing their positions, and 8 closing their positions.
550% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 2
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
16% more capital invested
Capital invested by funds: $103M → $120M (+$17M)
4% more funds holding
Funds holding: 46 → 48 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$7.05M |
| 2 |
GCL
Glazer Capital LLC
New York
|
+$5.69M |
| 3 |
FTCM
First Trust Capital Management
Chicago,
Illinois
|
+$5.35M |
| 4 |
CM
Cohanzick Management
Pleasantville,
New York
|
+$3.44M |
| 5 |
SCM
Saba Capital Management
New York
|
+$2.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Brown Advisory
Baltimore,
Maryland
|
-$11.1M |
| 2 |
KC
Kryger Capital
London,
United Kingdom
|
-$3.94M |
| 3 |
BCM
Basso Capital Management
Stamford,
Connecticut
|
-$1.67M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.47M |
| 5 |
SCM
Shaolin Capital Management
Miami,
Florida
|
-$1.34M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BCM
51
Basso Capital Management
Stamford,
Connecticut
| – | -$1.67M | -170,114 | Closed |
|
|
52
Alyeska Investment Group
Chicago,
Illinois
| – | -$1.47M | -150,000 | Closed |
|
|
SCM
53
Shaolin Capital Management
Miami,
Florida
| – | -$1.34M | -136,200 | Closed |
|
|
TCM
54
Tegean Capital Management
New York
| – | -$448K | -45,711 | Closed |
|
|
EH
55
EMG Holdings
Old Greenwich,
Connecticut
| – | -$98K | -10,000 | Closed |
|
56
CI Investments Inc
Toronto,
Ontario, Canada
| – | -$44K | -4,491 | Closed |
|
IBER Hedge Fund Activity: Q3 2022 in Review
48 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Ibere Pharmaceuticals (IBER) for Q3 2022, worth a combined $120M — up 16% from $103M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new IBER positions and 8 closed out — a net gain of 2 holders — while 13 added to existing stakes and 2 trimmed.
The largest buyer was Magnetar Financial, adding an estimated $7.05M. The largest seller was Brown Advisory, exiting entirely with an estimated $11.1M sold.
- 48 institutional investors held Ibere Pharmaceuticals (IBER) as of Q3 2022, up from 46 in Q2 2022.
- Funds reported $120M of Ibere Pharmaceuticals stock for Q3 2022, up 16% quarter-over-quarter.
- 10 funds opened new Ibere Pharmaceuticals positions in Q3 2022 and 8 closed out, a net change of +2 holders.
- The largest Ibere Pharmaceuticals buyer in Q3 2022 was Magnetar Financial, an estimated $7.05M added.
- The largest Ibere Pharmaceuticals seller in Q3 2022 was Brown Advisory, an estimated $11.1M sold.
Based on aggregated 13F filings for Q3 2022.